BioSpace News Archive

A double-blind, placebo-controlled, randomized clinical trial concluded at UCLA Medical Center shows how Freedom Softgels®, a newly developed nutritional supplement by Health Thru Nutrition, significantly reduced inflammatory markers in study subjects. [26-June-2019] LOS ANGELES , June 26, 2019 /PRNewswire/ -- This IRB approved study, conducted by Dr. Matthew Budoff

ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006.

Morphic Holding, Inc. announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per share.

OrthodontiCell, a biomed company focused on the development of therapeutics to accelerate tooth movement and improve stabilization, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for OrthodontiCell’s U.S. Patent Application Serial Number15/471,954 “Orthodontic Treatment”.

The L’AuRa platform enables robust diagnostic testing that is simple, compact and cost effective with no moving parts.

Invacare Corporation announced that Matthew E. Monaghan, chairman, president and chief executive officer will present at the 19th Annual “New Ideas” Summer Conference in Greenwich, CT, on Tuesday, July 9, 2019.

Quanterix Corporation announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock.

Cellectis S.A. held its Combined Shareholders Meeting (Euronext Growth: ALCLS; Nasdaq: CLLS) on June 25, 2019 at its head office in Paris

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity).

Catheter Precision, Inc., announced today that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO™ (View into Ventricular Onset) system for market release in the United States